Published in J Clin Invest on May 01, 2003
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest (2003) 2.18
The Treatment of Cushing's Disease. Endocr Rev (2015) 1.35
PPARγ is an E3 ligase that induces the degradation of NFκB/p65. Nat Commun (2012) 1.23
The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol Cell Biol (2009) 1.08
PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril (2007) 0.99
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol (2004) 0.92
The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res (2006) 0.92
Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment? Saudi Pharm J (2013) 0.90
Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res (2008) 0.88
Minireview: Nuclear receptor-controlled steroid hormone synthesis and metabolism. Mol Endocrinol (2009) 0.87
Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J (2007) 0.86
Thiazolidinediones on PPARγ: The Roles in Bone Remodeling. PPAR Res (2011) 0.85
Menin represses tumorigenesis via repressing cell proliferation. Am J Cancer Res (2011) 0.85
Medical treatment of Cushing's disease: Overview and recent findings. Int J Gen Med (2009) 0.84
Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol (2009) 0.84
PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice. Biol Reprod (2010) 0.83
PPAR Ligands for Cancer Chemoprevention. PPAR Res (2008) 0.83
Effect of troglitazone on radiation sensitivity in cervix cancer cells. Radiat Oncol J (2012) 0.82
A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology. PPAR Res (2008) 0.82
PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice. PPAR Res (2008) 0.81
Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med (2011) 0.78
PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis. PPAR Res (2012) 0.77
Developmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal Cord. J Neuroendocrinol (2016) 0.76
Rosiglitazone as an option for patients with acromegaly: a case series. J Med Case Rep (2011) 0.75
Peroxisome proliferator-activated receptor gamma signaling in human sperm physiology. Asian J Androl (2015) 0.75
Autocrine IL-6 mediates pituitary tumor senescence. Oncotarget (2016) 0.75
Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility. PPAR Res (2016) 0.75
Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study. BMC Cancer (2013) 0.75
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 11.72
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev (1994) 10.44
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 10.09
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell (1995) 7.99
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 6.69
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 6.53
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med (1994) 5.28
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell (1998) 3.71
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes (1996) 3.21
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem (1999) 2.13
Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol (1997) 1.82
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med (1999) 1.72
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.65
Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci U S A (1998) 1.38
Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J Biol Chem (2000) 1.36
Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab (2001) 1.32
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res (2000) 1.27
The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) (1993) 1.18
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun (1999) 1.00
Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol (2000) 0.96
Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) (2001) 0.96
Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol (2000) 0.93
Acromegaly: what constitutes optimal therapy? J Clin Endocrinol Metab (1996) 0.86
Rosiglitazone. Int J Clin Pract (2000) 0.85
Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf) (1986) 0.85
The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest (1981) 0.79
Clinical review 110: Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab (1999) 0.78
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res (2011) 2.29
Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.01
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev (2007) 1.79
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest (2011) 1.49
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab (2011) 1.34
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology (2003) 1.29
Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest (2002) 1.24
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab (2008) 1.19
Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A (2003) 1.19
Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol (2005) 1.18
Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab (2004) 1.15
Molecular targets in pituitary tumours. Nat Rev Cancer (2004) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol (2003) 1.09
Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary (2013) 1.08
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab (2008) 1.08
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest (2004) 1.06
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A (2011) 1.05
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology (2002) 1.04
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther (2010) 1.04
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab (2008) 1.03
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology (2006) 1.02
Securin is overexpressed in breast cancer. Mod Pathol (2005) 1.02
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab (2014) 0.96
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet (2011) 0.92
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab (2006) 0.90
Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab (2008) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology (2007) 0.89
Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol (2005) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab (2006) 0.89
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer (2010) 0.88
Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab (2012) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Heregulin regulates prolactinoma gene expression. Cancer Res (2009) 0.87
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J Med Chem (2009) 0.87
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab (2008) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Treatment of acromegaly: future. Endocrine (2005) 0.86
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab (2004) 0.86
Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab (2013) 0.86
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab (2003) 0.86
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol (2007) 0.85
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab (2009) 0.85
The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J Clin Endocrinol Metab (2003) 0.84
Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer (2011) 0.84
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Pituitary tumor transforming gene: an update. Front Horm Res (2004) 0.84
Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage. Endocr Relat Cancer (2014) 0.83
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem (2005) 0.83
Supplemental growth hormone in healthy adults: the endocrinologist's responsibility. Nat Clin Pract Endocrinol Metab (2006) 0.83
Skin manifestations in acromegaly. Clin Dermatol (2006) 0.83
Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am J Physiol Cell Physiol (2007) 0.83
Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab (2009) 0.83
Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs (2007) 0.83
Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Mol Endocrinol (2003) 0.82
A structural and functional acromegaly classification. J Clin Endocrinol Metab (2015) 0.82
Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression. Endocrinology (2003) 0.82
Pituitary tumour-transforming gene (PTTG) and pituitary senescence. Horm Res (2009) 0.82
Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol (2010) 0.82
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol (2012) 0.81
Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab (2003) 0.81
STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest (2015) 0.81
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. Endocrinology (2015) 0.80
Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Mol Endocrinol (2014) 0.80
In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. Dev Biol (2008) 0.80
Patient guide to hyperprolactinemia diagnosis and treatment. J Clin Endocrinol Metab (2011) 0.80
Acromegaly consensus: the next steps. J Clin Endocrinol Metab (2003) 0.80
Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocr Relat Cancer (2008) 0.80
Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab (2003) 0.80
Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle (2009) 0.80
Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. Mol Cell Endocrinol (2012) 0.79
CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol (2011) 0.79
Constitutive activity of somatostatin receptor subtypes. Methods Enzymol (2010) 0.79
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary (2010) 0.79
Genomic characterization of human and rat prolactinomas. Endocrinology (2012) 0.79
Molecular mechanisms of pituitary adenoma senescence. Front Horm Res (2010) 0.78
Pathogenesis of pituitary tumors. Prog Brain Res (2010) 0.78
Elevated circulating leukemia inhibitory factor in patients with extensive burns. J Burn Care Res (2006) 0.78